Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study

By sjmartinez • August 8, 2024

Kudo M, Tsuchiya K, Shao YY, Finn RS, Galle PR, Ducreux M, Cheng AL, Yamashita T, Koga H, Take R, Yamada K, Asakawa T, Nakagawa Y, Ikeda M. Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study. Liver Cancer. 2023 Nov 28;13(4):401-412. doi: 10.1159/000535501. PMID: 39114762; PMCID: PMC11305667.

Tags: Adverse events of special interest, Atezolizumab, Bevacizumab, Hematology/Oncology, Publications, Skipped bevacizumab, Unresectable hepatocellular carcinoma

Related Posts

Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate

Schoen MW, Li J, Zeng S, Desai H, Hausler R, Haroldsen CL, Owens L, Valle LF, Etzoni RB, Rebbeck TR, Rose BS, Kelley MJ, Montgomery[...]

Impact of metastatic pattern and histologic subtype on PD-(L)1 inhibitor efficacy in HER2-negative advanced gastric and gastroesophageal cancer: a meta-analysis

Tai D, Kim KI, Shah P, Park D, Kim L, Li J, Jung C, Guzman S, Brar G, Wu S, Castillo D. Impact of metastatic[...]

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Srour SA, Chahoud J, Drakaki A, Curti BD, Gibney GT, Tang L, Jiang Y, Charmsaz S, Robbins PB, McLeroy J, Severyn CJ, Le Gall JB,[...]